Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a gentle nerve zap ease jaw pain? new study tests it

NCT ID NCT07288411

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 02, 2026 · Updated 5 times

Summary

This pilot study will test whether a non-invasive vagus nerve stimulation (nVNS) device can reduce jaw pain and improve mood in 10 premenopausal women with temporomandibular disorders (TMD). Participants will receive the treatment twice a week for 8 weeks and undergo brain scans, blood draws, and questionnaires. The goal is to see if this nerve-stimulating approach affects pain and brain-gut pathways.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
non-invasive vagus nerve stimulation (nVNS) device
What this could lead to
If it works, this could point toward a drug-free way to reduce jaw pain and improve mood in women with TMD.
What could go wrong
This is a very small pilot study with only 10 people, so results may not apply widely. It is early-stage and may not show clear benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Ages 18-50 * Premenopausal menstruating women\* * Participants report or present with at least 1 of 3 cardinal signs of TMD: jaw pain, limited mouth opening, or TMJ noise. * Specific screening reveals clinical findings that include TMJ and/or masticatory and cervical muscle pain. * Must have a negative urine test for pregnancy * Ability to speak the English language fluently due to the standardized assessments involved * Right-handed (participants are limited to right-handed individuals to reduce variability in brain lateralization and ensure more consistent, interpretable data). * Only premenopausal women are included to control for hormonal variability that may influence the results. Participants will be scheduled during their follicular phase based on self-reported last menstrual period to further reduce hormonal confounds. Exclusion Criteria: * Medical condition, laboratory finding, or physical exam finding that precludes participation, such as systemic arthritides, juvenile idiopathic arthritis, idiopathic condylar resorption, connective tissue disorders, mandibular osteonecrosis, mandibular and condylar fractures, salivary gland disorders (incl. history of stones or swelling), neoplasms, neurologic/neuropathic, endocrine, or immune/autoimmune diseases and congenital or developmental disorders. * Pathologic processes found on imaging including neoplasm (Exception: disc displacements and osseous pathology including osteoarthritis/osteoarthrosis). * Radiation treatment to head and neck * Prior jaw or open TMJ (including contralateral joint) surgery including plication, chondroplasty, joint replacement, disectomy, and discoplasty. * Intra-articular therapies of TMJ being sampled that include arthrocentesis, visco-supplementation, and steroid, platelet-rich plasma/platelet-rich fibrin administration within the last 6mo * Recent febrile illness within the past 8 weeks that precludes or delays participation by more than 90 days * Trauma to jaw in the last 2mo * Presence of non-TMD orofacial pain disorders excluding comorbidity of interest (fibromyalgia). * Pregnancy or lactation * Undergoing or previously undergone bone anabolic or other hormonal therapies for medical needs * Unable to participate due to language barrier or mental/intellectual incompetence * Use of antidepressant drugs unless the participants have been on a stable dose for 60 days. * Drug and/or alcohol abuse in the past year * Ongoing dental treatments requiring invasive procedures (e.g. implant placement, tooth extractions, etc.) * Recent dental treatments within past two weeks that required sustained mouth opening for more than 20 minutes. * Wearing removable or implant supported dentures or fixed orthodontic appliances * Unable or unwilling to give informed consent * Participation in another clinical study that interferes with participation in this study * Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study. * Presence of non-TMD orofacial pain disorders such as that from periodontal disease and carious lesions. * Presence of major psychiatric diagnosis such as schizophrenia, bipolar disorder, post-traumatic stress disorder, obsessive compulsive disorder, or current history of drug or alcohol abuse. * Individuals with current regular use of narcotics and/or opioids. Use of centrally acting medications that will interfere with neuroimaging testing, such as systemic steroids, opiate analgesics. * Smokes/Vapes tobacco more than 1/3 pack per day

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Temporomandibular disorders (TMDS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of California, Los Angeles

    RECRUITING

    Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.